Federal Register #2026-14981

NCI Seeks Partners for NPM1 Mutation-Specific T Cell Receptors for AML Therapy

The National Cancer Institute (NCI), part of the National Institutes of Health under the Department of Health and Human Services, is seeking partners for a government-owned invention targeting Acute Myeloid Leukemia (AML): - Government Buyer: - Department of Health and Human Services - National Institutes of Health - National Cancer Institute - Technology Offered: - NPM1 Mutation-Specific T Cell Receptors (TCR6 and TCR7) - Designed for targeted adoptive T cell therapy in AML patients expressing the NPM1 mutation and HLAA*11:01 - Recognizes the neoepitope AVEEVSLRK derived from mutant NPM1 - Product Details: - Part number: E20020250 - Pre-clinical validation stage - Demonstrated robust, specific cytotoxicity against AML cell lines and patient-derived samples - No cross-reactivity to normal cells or unrelated HLA alleles, indicating a strong safety profile - Opportunity Type: - Seeking research co-development partners or licensees - No commercial OEMs or vendors are named; this is a government-owned invention - Unique Requirements: - Focus on AML patients with HLAA*11:01 and NPM1 mutation - Technology is intended for adoptive T cell therapy applications - Emphasis on specificity and safety in targeting cancer cells

Description

The National Cancer Institute (NCI) is seeking research co-development partners or licensees for NPM1 Mutation-Specific T Cell Receptors aimed at targeted treatment of Acute Myeloid Leukemia (AML). This invention involves two highly specific T cell receptors, TCR6 and TCR7, which recognize a neoepitope derived from mutant NPM1 presented in the context of HLAA*11:01. Pre-clinical results show robust and specific cytotoxicity against leukemia cell lines and patient-derived AML samples expressing the NPM1 mutation and HLAA*11:01, with no cross-reactivity to normal cells or unrelated HLA alleles. The technology represents a potential adoptive T cell therapy for AML with a significant unmet medical need and enhanced safety profile.

View original listing